ASTRAZEN — Astrazeneca Pharma India Share News
0.000.00%
Last trade - 00:00- IN₹149.71bn
- IN₹146.34bn
- IN₹22.76bn
Brief: Astrazeneca Pharma India Gets Final Tax Assessment Order Of 140.8 Mln Rupees
Brief: Astrazeneca Pharma India June-Qtr Loss After Tax 117.9 Mln Rupees
Brief: Astrazeneca Pharma India Receives Permission For Voluntary Withdrawal Of Indication Of Olaparib (Lynparza)
Brief: Astrazeneca Pharma India Gets Permission To Import For Sale And Distribution Of Trastuzumab Deruxtecan Lyophilized Powder
Brief: Mankind Pharma and Astrazeneca Pharma India Enter Exclusive Distribution Agreement
Brief: Astrazeneca Pharma India Says BSE And NSE Have Imposed A Fine Of 217,120 Rupees Each On Co
AstraZeneca Pharma India tanks on quarterly profit drop
AstraZeneca Pharma India surges 19% to fresh record high
Astrazeneca Pharma India up on plans to launch breast cancer drug in Jan
Brief: Astrazeneca Pharma India Will Launch Enhertu In January 2024 In India
India's Astrazeneca Pharma rises after Q1 profit jump
Astrazeneca Pharma India hits 2-year high on regulatory import approval
Brief: Astrazeneca Pharma India Receives Permission To Import Pharmaceutical Formulations For Dapagliflozin
Brief: Astrazeneca Pharma India Received Permission To Import For Sale And Distribution Of Tremelimumab (Imjudo)
Astrazeneca Pharma India up 6% on core profit growth in March qtr
Brief: Astrazeneca Pharma India Appoints Bhavana Agrawal As CFO
India's Astrazeneca Pharma gains 2% on nod to import breast cancer drug
Brief: Astrazeneca Pharma India Gets Nod In Form CT-20 To Import For Sale And Distribution Of Trastuzumab Deruxtecan (Enhertu) 100mg/5ml Vial Lyophilized Powder
Brief: Astrazeneca Pharma India Received No Objection From Central Drugs Standard Control Organisation